LABORATORY AND CLINICAL STUDIES OF MEROPENEM IN RESPIRATORY TRACT INFECTION

• Published in: CHEMOTHERAPY Vol. 40; no. Supplement1; pp. 283 - 287
• Main Authors: Matsumoto, Hiroyuki, Ohki, Yasuo, Onodera, Sokichi, Hiroshima, Takashi, Sasaki, Nobuhiro, Tsuji, Tadakatsu, Nakano, Hitoshi, Osaki, Yoshinobu, Fujikane, Toshiaki, Shimizu, Tetsuo, Fujita, Yuka, Fujiuchi, Satoshi, Sakai, Eiichi
• Format: Journal Article
• Language: English; Japanese
• Published: Japanese Society of Chemotherapy 1992; 公益社団法人 日本化学療法学会
• Subjects: Meropenem; 呼吸器感染症; 喀痰中移行
• ISSN: 0009-3165; 1884-5894
• DOI: 10.11250/chemotherapy1953.40.Supplement1_283

Laboratory and clinical studies on meropenem (MEPM), a novel carbapenem antibiotic, were performed, and the results were as follows. 1) When 500mg of MEPM was intravenously administrated by 30min drip infusion in patients with pneumonia, the peak plasma levels were 24.2μg/ml and 26.0μg/ml. The peak sputum levels were0.48μg/ml and 3.90μg/ml at 2h after infusion. 2) MEPM was administrated to 13 patients with respiratory tract infections: 11 with pneumonia, 1with pulmonary abscess and 1 with suppurative disease of the lung. Clinical efficacy was rated as excellent in 3, good in 5 and fair in 2, an efficacy rate of 80%. 3) No side effects were observed, but one of 13 patients showed elevated eosinophils and GPT.